


Biotech and the global burden of disease

08 January 2004 | News



With rapidly increasing consumer awareness, only those technologies will survive in the future that would bring a definable and desirable benefit to the consumer, or help people or government to achieve significant progress. This would be true of biotechnology as of, say, space or new energy targets.

One area where humanity expects a great contribution from biotechnology is in respect of management of diseaseâ€"that is, reducing the global burden of disease. What, then, is this global burden of disease? Following a recent study (Ezzati et al., The Lancet, 2002, Vol. 360, pp.1347-1360), this burden can now be stated in precise terms.

The above study used data collected from 192 countries around the world. The factors listed in Table 1 were identified as the main causative factors for the diseases mentioned against each factor, different countries contributing to a different extent to the total global disease burden on account of a particular factor.

The question we may ask is, where and how can biotechnology contribute to alleviate global suffering on account of the 26 factors mentioned in Table 1. This contribution could be towards prevention of, better and more expedient diagnosis of, and/or cure for a disease. Let me give examples.

To take care of vitamin A deficiency mentioned under item 3 in table 1, we need to be able to provide cheap natural beta-carotene, the precursor of vitamin A, which could be used in mid-day meal program in schools. Shantha Marine is already making inexpensive beta-carotene using a marine algae, seawater and sunlight, in their factory in Tiruchendur, TamilNadu.

This is an example of how marine biotechnology can provide inexpensive material to take care of one important global burden of disease. However, this is also an example where it is not only the availability of the material but also a concurrent systems approach on part of the government which would ensure that this material is actually appropriately used, that would be important.

Monoclonal antibodies (MABs) have proved invaluable as agents of diagnosis of a large number of diseases or for determining the genetic susceptibility status of an individual in respect of a disease. It is a pity that, as of now, not a single monoclonal antibody of Indian origin is in the market. We not only need to fill in this lacuna but also develop newer MABs for diagnosis of disorders that are common for us.

Preventive vaccines for diseases such as AIDS, malaria and tuberculosis represent another major need of the time. The production of these vaccines through innovative modern biotechnological routes grounded in imaginative basic research, alone would make them possible and economically feasible.

Those interested in biotechnology and medical health care would be doing a tremendous service if they could collectively prepare a document which would state how biotechnology could reduce the global burden of disease, through development of specific preventive, diagnostic and curative regimens, I believe that *BioSpectrum* is the right vehicle for starting a debate on the above question: that is, how could we, individually and collectively, have biotechnology discharge the above responsibility.

Pushpa M Bhargava is one of India's most brilliant scientists. He founded and directed the Centre for Cellular and Molecular Biology (CCMB), Hyderabad.

Factors responsible for the global burden of disease

| S No. | Factor | Outcome |
|-------|--------------------------------|--|
| 1 | | Mortality and acute morbidity from diarrhoea, malaria, measles, pneumonia and selected other group 1 diseases; perinatal conditions from maternal underweight; long-term morbidity from under nutrition |
| 2 | Iron deficiency | Anaemia and its sequelae (including cognitive impairment); maternal and perinatal mortality |
| 3 | | Mortality due to diarrhoea, measles, malaria and miscellaneous infection causes of disease (children<5 years); morbidity due to malaria (children<5 years); maternal morbidity and mortality (pregnant women); vitamin A deficiency and its sequelae (all age groups); low birth weight and other perinatal conditions |
| 4 | Zinc deficiency | Diarrhoea; pneumonia; malaria in children aged<5 years; adult and pregnancy outcomes |
| 5 | High blood pressure | Ischaemic heart disease (IHD); stroke; hypertensive heart disease and other cardiovascular diseases; renal failure |
| 6 | High cholesterol | IHD; stroke; other cardiovascular diseases |
| 7 | | IHD; stroke; hypertensive heart disease; diabetes; osteoarthritis; and obesity)endometrial and colon cancers; post-menopausal breast cancer; gallbladder cancer; kidney cancer; breathlessness; back pain; dermatitis; menstrual disorders and infertility; gallstones |
| 8 | Low fruit and vegetable intake | IHD; stroke; colorectal cancer; gastric cancer; lung cancer oesophageal cancer |
| 9 | Physical inactivity | IHD; breast cancer; colon cancer; diabetes; falls and osteoporosis; osteoarthritis; lower back pain; prostate and rectal cancer |

| 10 | Unsafe sex | HIV/AIDS; sexually transmitted infections; cervical cancer |
|----|--------------------------------------|---|
| 11 | Lack of contraception | Maternal mortality and morbidity; increased perinatal and child mortality |
| 12 | Tobacco | Lung cancer; upper aerodigestive cancer; all other cancers; chronic obstructive pulmonary disease (COPD); other respiratory diseases; all vascular diseases and other medical causes in adults > 30; fire injuries; maternal outcomes and perinatal conditions |
| 13 | Alcohol | IHD; stroke; hypertensive heart disease; diabetes; liver cancer; mouth and oropharynx cancer; breast cancer; oesophagus cancer; selected other cancers; liver cirrhosis; epilepsy; alcohol disorders; depression; intentional and unintentional injuries; selected other cardiovascular diseases and cancers; social consequences |
| 14 | Illicit drugs | HIV/AIDS; overdose-of-drug-use disorders; suicide and trauma; other neuropsychological diseases; social consequences; hepatitis B and hepatitis C |
| 15 | Unsafe water, sanitation and hygiene | Diarrhoea |
| 16 | Urban outdoor air pollution | Mortality from combined respiratory and selected cardiovascular causes in adults >30; lung cancer; acute respiratory infection mortality in children <5; cardiovascular and respiratory morbidity |
| 17 | Indoor smoke from solid fuels | Acute lower respiratory infections in children <5; COPD; lung cancer, cataracts; tuberculosis; asthma |
| 18 | Lead | Cardiovascular diseases; mild mental retardation; anaemia; gastrointestinal effects; nervous and reproductive system effects; social consequences of IQ loss |
| 19 | Global climate change | Diarrhoea; flood injury; malaria; malnutrition; dengue fever; cardiovascular mortality; effects arising from population movement |
| 20 | Risk factors for injuries | Unintentional injuries; intentional injuries |
| 21 | Carcinogens | Leukemia; lung cancer; mesothelioma; cancers of multiple other sites |
| 22 | Airborne particulates | COPD and asthma; pneumoconiosis; silicosis; asbestosis |
| 23 | Ergonomic stressors | Lower back pain |
| 24 | Noise | Hearing loss |
| 25 | Unsafe health-care injections | Acute infection with HBV, HCV and HIV; cirrhosis and liver cancer; selected other infectious diseases |
| 26 | Childhood sexual abuse | Depression; panic disorder; alcohol misuse/dependence; drug misuse/ dependence; post-traumatic stress disorder and suicide in adulthood; non mental health outcomes such as sexually transmitted diseases, unwanted pregnancies and injuries |

Note: Factors 1-4 relate to childhood and maternal under nutrition; 5-9 to other nutrition-related risks and physical activity; 10-11 to sexual and reproductive health; 12-14 to addictive substances; 15-19 to environmental risks; and 20-24 to occupational risks. (Adapted from M. Ezzati *et. al.*, *The Lancet*, Vol. 360, November 2, 2002, pp. 1347-1360)